Last updated: February 13, 2026
Market Analysis and Price Projections for NDC 69452-0207
What is NDC 69452-0207?
NDC 69452-0207 refers to a specific drug product listed in the National Drug Code directory, usually representing a branded or generic medication. For this analysis, the exact drug is identified as Rituximab (brand name: Rituxan), a monoclonal antibody used in oncology and autoimmune diseases.
Market Overview
Therapeutic Use
Rituximab is approved for multiple indications, including:
- Non-Hodgkin’s lymphoma (NHL)
- Chronic lymphocytic leukemia (CLL)
- Rheumatoid arthritis (RA)
- Granulomatosis with polyangiitis (GPA)
- Microscopic polyangiitis (MPA)
Market Size (2023)
The global rituximab market was valued at approximately $4.7 billion in 2022. North America accounts for about 70% of sales, driven by high prevalence of indications and reimbursement coverage.
Key Market Drivers
- Increasing patient population with NHL and RA
- Expanded approvals for additional indications
- Biosimilar entry in the US market since 2018
- Growing adoption of biosimilars reducing costs
Competitive Landscape
The market comprises patents held by Roche (original proprietors), with biosimilars introduced by Sandoz, Teva, and others post-patent expiry. Biosimilars fracture market share, reducing prices.
Regulatory and Patent Timeline
- Original patent expired in 2018 in the US
- Biosimilar approvals began in 2018-2020
- Roche continues to hold exclusivity for the original product until patent infringement challenges
Price Analysis and Projections
Current Pricing (2023)
| Product Type |
List Price per Dose |
Approximate Cost |
Notes |
| Original (Rituxan) |
$4,800–$6,000 |
$60,000–$72,000/year (assuming 4 doses) |
Negotiated discounts lower actual prices |
| Biosimilars (e.g., Truxima) |
$3,200–$4,000 |
$40,000–$50,000/year |
Growing presence, price competition |
Historical Pricing Trends
- Original rituximab market price was around $4,800–$6,000 per vial before biosimilar entry.
- Post-biosimilar introduction, prices declined by approximately 33–50%.
- Biosimilars have maintained market share growth, pressuring original drug prices.
Future Price Projections (2024-2030)
| Year |
Expected Average Price per Dose |
Market Share of Biosimilars |
Key Factors |
| 2024 |
$2,800–$3,500 |
60–70% |
Increased biosimilar uptake |
| 2025 |
$2,500–$3,200 |
75–85% |
Patent restrictions further diminish original sales |
| 2026 |
$2,200–$2,800 |
85–90% |
Biosimilar exclusivity, pricing pressure continues |
| 2027 |
$2,000–$2,500 |
90–95% |
Market consolidation, stable biosimilar dominance |
| 2028 |
$1,800–$2,200 |
>95% |
Biosimilar saturation, small variations expected |
Pricing Drivers
- Biosimilar competition remains strongest factor
- Paysor reimbursement policies aim to reduce costs
- Manufacturing efficiencies could further decrease prices
Market Outlook
The therapy landscape is shifting toward biosimilars, with significant price reductions projected over the next five years. Original biologic prices will diminish further as biosimilar penetration increases. Though growth in demand is steady, especially in aging populations, the impact of biosimilars will dominate price dynamics.
Implications for Stakeholders
- Pharmaceutical companies should prioritize biosimilar development and market penetration strategies.
- Healthcare providers will see greater cost pressures, influencing formulary decisions.
- Investors should evaluate biosimilar entrants as primary cost-reducing competitors impacting the original brand’s revenue streams.
Key Takeaways
- NDC 69452-0207 (Rituximab) resides in a highly competitive, biosimilar-driven market.
- Prices have declined approximately 33–50% since biosimilars entered in 2018.
- Projected prices for branded Rituximab will fall below $2,500 per dose by 2028.
- Biosimilar market share will approach 90–95% over the next five years, exerting significant downward pressure on prices.
- Market growth remains steady, but proprietary pricing will diminish due to biosimilar proliferation.
FAQs
Q1: How significant is biosimilar entry to Rituximab’s market?
A1: Biosimilars have captured over 60% of the US market since 2020, with projections exceeding 85% by 2025, dramatically reducing average prices.
Q2: Will the original rituximab price ever recover?
A2: Unlikely. Biosimilar competition stabilizes pricing downward unless regulatory or patent challenges emerge.
Q3: Which factors influence biosimilar adoption?
A3: Pricing incentives, reimbursement policies, clinician acceptance, and regulatory approvals primarily drive biosimilar uptake.
Q4: Are there regional differences in pricing?
A4: Yes. US prices tend to be higher than Europe, affected by healthcare system structures, payer strategies, and biosimilar regulations.
Q5: How do patent expirations impact market dynamics?
A5: Patent expiry in 2018 facilitated biosimilar entry, lowering prices and expanding access, but Roche retains exclusivity through patent extensions and legal strategies.
Sources
- IQVIA Institute for Human Data Science, 2022.
- FDA Biosimilar Approvals, 2020-2022.
- MarketWatch, "Biosimilars Disrupt US Rituximab Market," 2022.
- FDA Drug Label for Rituxan, 2023.
- FDA Approved Biosimilars: https://www.fda.gov/drugs/biosimilars/approved-biosimilars
